

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications  
under 37 CFR 1.53(b))

Attorney Docket No. **C1037/7017HCL/MAT**

First Named Inventor or Application Identifier

**BRATZLER, Robert L.**

Express Mail Label No. **EL711263038US**

Date of Deposit **March 5, 2001**

OLD  
S.N. 666666  
J06000/00

10/50/00

## APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents

1. ☐ Fee Transmittal Form  
(Submit an original, and a duplicate for fee processing)
2. ☐ Applicant claims small entity status.  
See 37 CFR 1.27.  
☐ Statement filed in prior application, status still proper and desired.
3. ☒ Specification - Total pages - 73  
66 - pages description  
1 - pages abstract  
6 - pages claims 36 - Total claims
4. ☐ Drawing(s) (35 USC 113) - Total sheets  
☐ Informal ☐ Formal - Total drawings
5. ☐ Oath or Declaration - Total pages  
a. ☐ Newly executed (original or copy)  
b. ☐ Copy from a prior application (37 CFR 1.63(d))  
(for continuation/divisional with Box 18 completed)  
[Note Box 6 below]  
i. ☐ DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6. ☐ Incorporation by Reference  
(usable if Box 5b is checked)  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein. See 18.
7. ☐ Application Data Sheet, See 37 CFR 1.76

ADDRESS Box Patent Application  
TO: Commissioner for Patents  
Washington, DC 20231

8. ☐ CD-ROM or CD-R, in duplicate, large table or Computer Program (Appendix)
9. ☒ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
  - a. ☒ Computer Readable Form (CRF)
  - b. ☐ Specification Sequence Listing on:
    - i. ☐ CD-ROM or CD-R (2 copies); or
    - ii. ☒ X paper (identical to computer copy)
  - c. ☒ Statement verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

10. ☐ Assignment Papers/cover sheet & documents(s)
11. ☐ 37 CFR 3.73(b) Statement  
(when there is an assignee)  
☐ Power of Attorney
12. ☐ English Translation of Document (if applicable)
13. ☐ Information Disclosure Statement/PTO-1449  
☐ Copies of IDS Citations
14. ☐ Preliminary Amendment
15. ☒ Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
16. ☐ Certified Copy of Priority Document(s)  
(if foreign priority is claimed)
17. ☒ This application claims priority under Title 35 §119(e), of United States Provisional Application No. 60/187,214, filed March 3, 2000, and entitled IMMUNOSTIMULATORY NUCLEIC ACIDS AND CANCER MEDICAMENT COMBINATION THERAPY FOR THE TREATMENT OF CANCER, the entire contents of which are incorporated herein by reference.

18. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in the body of the application, or a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: \_\_\_\_\_, filed on \_\_\_\_\_, entitled \_\_\_\_\_ and now \_\_\_\_\_.

Prior application information: Examiner \_\_\_\_\_ Group Art Unit: \_\_\_\_\_

For CONTINUATION OR DIVISIONAL APPS only The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

Correspondence address below

CUSTOMER NUMBER



**23628**

PATENT TRADEMARK OFFICE

20. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

NAME

Helen C. Lockhart, Reg. No. 39248

SIGNATURE

DATE

March 5, 2001

**Express Mail No: EL711263038US**

**Date of Deposit: March 5, 2001**

**Attorney Docket No: C1037/7017**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: BRATZLER, Robert L. et al.  
Filed: Herewith  
For: IMMUNOSTIMULATORY NUCLEIC ACIDS AND  
CANCER MEDICAMENT COMBINATION THERAPY FOR  
THE TREATMENT OF CANCER


Box: Patent Application  
Assistant Commissioner for Patents  
Washington, D.C. 20231

**STATEMENT PURSUANT TO 37 CFR 1.821(f)**

Sir:

This statement is made pursuant to 37 CFR 1.821(f). Applicant encloses herewith a copy of the Sequence Listing and a computer readable diskette. Applicant's attorney states that the content of the paper copy of the Sequence Listing and the computer readable diskette contain the identical information.

Respectfully submitted,



Helen C. Lockhart  
Reg. No. 39,248  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, MA 02210-2211  
(617)720-3500

Docket No.C1037/7017  
March 5, 2001  
**X03/03/01**